Gerald Clarke | 08/29/2013
The words Bioelectronic medcine conjour up futuristic images of human-computer integegration that seem more sci-fi than science. GSK however view this as a promising medicinal area as demonstrated by their founding of their Bioloectronics research group and their more recent announcement of a $50m venture capital fund Action Potential Venture Capital which is seeking to invest in this field. Pharma IQ caught up with Imran Eba, partner at Action Potential to discuss this exciting future pharma...
To continue reading this story Click Here
Upcoming Events
GenAI Life Science & Health 2025
September 1 - 3, 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More

DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
